Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GLPG1205 in Healthy Japanese and Caucasian Males
NCT04532567Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG1205 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Galapagos NV. Primary endpoints: Treatment Emergent Adverse Events, Maximum observed plasma concentration at Day 32 and 2 more. Started Aug 2020; status: completed.
02
Drugs
GLPG1205
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04532567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532567.